Emerging Role of Angiotensin Type 2 Receptor (AT2R)/Akt/NO Pathway in Vascular Smooth Muscle Cell in the Hyperthyroidism

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Carrillo Sepúlveda, Maria Alícia ^a   Ceravolo, Graziela S ^a   Furstenau, Cristina R ^a   de Monteiro, Priscilla Souza ^a   Bruno Fortes, Zuleica ^a   Carvalho, Maria Helena ^a   Laurindo, Francisco R ^a   Tostes, Rita C ^a,b   Webb, R Clinton ^b   Barreto Chaves, Maria Luiza M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALPHA ACTIN; ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN II; CALPONIN; LIOTHYRONINE; MYOSIN LIGHT CHAIN; NITRIC OXIDE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RENIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; AT2R GENE; BLOOD VESSEL REACTIVITY; CELL STIMULATION; CONTROLLED STUDY; GENE EXPRESSION; HYPERTHYROIDISM; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SMOOTH MUSCLE FIBER; VASCULAR ENDOTHELIUM; VASCULAR RING; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANGIOTENSIN II; ANIMALS; AORTA; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; HYPERTHYROIDISM; MALE; MODELS, BIOLOGICAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RECEPTOR, ANGIOTENSIN, TYPE 2; SIGNAL TRANSDUCTION; TRIIODOTHYRONINE; VASOCONSTRICTION;

ANIMALIA; RATTUS;

EID: 84876583572     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061982     Document Type: Article

References (54)

1. Caldwell KL, Makhmudov A, Ely E, Jones RL, Wang RY, (2008) Iodine status of the U.S. population, National Health and Nutrition Examination Survey, 2005-2006 and 2007-2008. Thyroid 21: 419-427.
2. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC, (2000) The Colorado thyroid disease prevalence study. Arch Intern Med 160: 526-534.
3. Klein I, Ojamaa K, (2001) Thyroid hormone and the cardiovascular system. N Engl J Med 344: 501-509.
4. McAllister RM, Albarracin I, Price EM, Smith TK, Turk JR, et al. (2005) Thyroid status and nitric oxide in rat arterial vessels. J Endocrinol 185: 111-119.
5. Carrillo-Sepúlveda MA, Ceravolo GS, Fortes ZB, Carvalho MH, Tostes RC, et al. (2010) Thyroid hormone stimulates NO production via activation of the PI3K/Akt pathway in vascular myocytes. Cardiovasc Res 85: 560-570.
6. Hu LW, Benvenutti LA, Liberti EA, Carneiro-Ramos MS, Barreto-Chaves ML, (2003) Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling. Am J Physiol Regul Integr Comp Physiol 285: R1473-R1480.
7. Fukuyama K, Ichiki T, Takeda K, Tokunou T, Lino N, et al. (2003) Downregulation of vascular angiotensin II type 1 receptor by thyroid hormone. Hypertension 41: 598-603.
8. Carneiro-Ramos MS, Diniz GP, Nadu AP, Almeida J, Vieira RL, et al. (2010) Blockage of angiotensin II type 2 receptor prevents thyroxine-mediated cardiac hypertrophy by blocking Akt activation. Basic Res Cardiol 105: 325-335.
9. Diniz GP, Carneiro-Ramos MS, Barreto-Chaves ML, (2009) Angiotensin type 1 receptor mediates thyroid hormone-induced cardiomyocyte hypertrophy through the Akt/GSK-3beta/mTOR signaling pathway. Basic Res Cardiol 104: 653-667.
10. Murphy TJ, Takeuchi K, Alexander RW, (1992) Molecular cloning of AT1 angiotensin receptors. Am J Hypertens 5: 236S-242S.
11. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, et al. (1993) Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 268: 24543-24546.
12. Akishita M, Horiuchi M, Yamada H, Zhang L, Shirakami G, et al. (2000) Inflammation influences vascular remodeling through AT2 receptor expression and signaling. Physiol Genomics 2: 13-20.
13. Carey RM, (2005) Cardiovascular and renal regulation by the angiotensin type 2 receptor: the AT2 receptor comes of age. Hypertension 45: 840-844.
14. Hannan RE, Davis EA, Widdop RE, (2003) Functional role of angiotensin II AT2 receptor in modulation of AT1 receptor-mediated contraction in rat uterine artery: involvement of bradykinin and nitric oxide. Br J Pharmacol 140: 987-995.
15. Horiuchi M, Akishita M, Dzau VJ, (1999) Recent progress in angiotensin II type 2 receptor research in the cardiovascular system. Hypertension 33: 613-621.
16. Widdop RE, Jones ES, Hannan RE, Gaspari TA, (2003) Angiotensin AT2 receptors: cardiovascular hope or hype? Br J Pharmacol 140: 809-824.
17. You D, Loufrani L, Baron C, Levy BI, Widdop RE, et al. (2005) High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats. Circulation 111: 1006-1111.
18. Siragy HM, Carey RM, (1996) The subtype-2 (AT2) angiotensin receptor regulates renal cyclic guanosine 3′, 5′-monophosphate and AT1 receptor-mediated prostaglandin E2 production in conscious rats. J Clin Invest 97: 1978-1982.
19. Siragy HM, Carey RM, (1997) The subtype 2 (AT2) angiotensin receptor mediates renal production of nitric oxide in conscious rats. J Clin Invest 100: 264-269.
20. Abadir PM, Carey RM, Siragy HM, (2003) Angiotensin AT2 receptors directly stimulate renal nitric oxide in bradykinin B2-receptor-null mice. Hypertension 42: 600-604.
21. Macari D, Whitebread S, Cumin F, De Gasparo M, Levens N, (1994) Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 259: 27-36.
22. Ross R, (1971) The smooth muscle cell. II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol 50: 172-186.
23. Siragy HM, Inagami T, Carey RM, (2007) NO and cGMP mediate angiotensin AT2 receptor-induced renal renin inhibition in young rats. Am J Physiol Regul Integr Comp Physiol 293: R1461-1467.
24. Foster FM, Traer CJ, Abraham SM, Fry MJ, (2003) The phosphoinositide (PI) 3-kinase family. J Cell Sci 116: 3037-3040.
25. Alves GM, Barão MA, Odo LN, Nascimento Gomes G, Franco MC, et al. (2002) L-Arginine effects on blood pressure and renal function of intrauterine restricted rats. Pediatr Nephrol 17: 856-862.
26. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
27. Nakatsubo N, Kojima H, Kikuchi K, Nagoshi H, Hirata Y, et al. (1998) Direct evidence of nitric oxide production from bovine aortic endothelial cells using new fluorescence indicators: diaminofluoresceins. FEBS Lett 427: 263-266.
28. Vargas F, Moreno JM, Rodriguez-Gomez I, Wangensteen R, Osuna A, et al. (2006) Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol 154: 197-212.
29. Gohlke P, Pees C, Unger T, (1998) AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 31: 349-355.
30. Caruso-Neves C, Kwon SH, Guggino WB, (2005) Albumin endocytosis in proximal tubule cells is modulated by angiotensin II through an AT2 receptor-mediated protein kinase B activation. Proc Natl Acad Sci USA 102: 17513-17518.
31. Hiroi Y, Kim HH, Ying H, Furuya F, Huang Z, et al. (2006) Rapid nongenomic actions of thyroid hormone. Proc Natl Acad Sci USA 103: 14104-14109.
32. Mizuma H, Murakami M, Mori M, (2001) Thyroid hormone activation in human vascular smooth muscle cells: expression of type II iodothyronine deiodinase. Circ Res 88: 313-318.
33. Barreto-Chaves ML, de Souza Monteiro P, Fürstenau CR, (2011) Acute actions of thyroid hormone on blood vessel biochemistry and physiology. Curr Opin Endocrinol Diabetes Obes 18: 300-303.
34. Barreto-Chaves ML, Carrillo-Sepúlveda MA, Carneiro-Ramos MS, Gomes DA, Diniz GP, (2010) The crosstalk between thyroid hormones and the Renin-Angiotensin System Vascul Pharmacol. 52: 166-170.
35. Biondi B, Palmieri EA, Lombardi G, Fazio S, (2002) Effects of thyroid hormone on cardiac function: the relative importance of heart rate, loading conditions, and myocardial contractility in the regulation of cardiac performance in human hyperthyroidism. J Clin Endocrinol Metab 87: 968-974.
36. Danzi S, Klein I, (2004) Thyroid hormone and the cardiovascular system. Thyroid hormone and the cardiovascular system. Minerva Endocrinol 29: 139-150.
37. Kahaly GJ, Dillmann WH, (2005) Thyroid hormone action in the heart. Endocr Rev 26: 704-728.
38. Abe A, Yamamoto T, Isome M, Ma M, Yaoita E, et al. (1998) Thyroid hormone regulates expression of shaker-related potassium channel mRNA in rat heart. Biochem Biophys Res Commun 245: 226-230.
39. Gloss B, Trost S, Bluhm W, Swanson E, Clark R, et al. (2001) Cardiac ion channel expression and contractile function in mice with deletion of thyroid hormone receptor alpha or beta. Endocrinology 142: 544-550.
40. Boerth SR, Artman M, (1996) Thyroid hormone regulates Na(+)-Ca2+ exchanger expression during postnatal maturation and in adult rabbit ventricular myocardium. Cardiovasc Res 31: E145-E152.
41. Rodríguez-Gómez I, Sainz J, Wangensteen R, Moreno JM, Duarte J, et al. (2003) Increased pressor sensitivity to chronic nitric oxide deficiency in hyperthyroid rats. Hypertension 42: 220-225.
42. Hashimoto T, Kihara M, Ishida J, Imai N, Yoshida S, et al. (2006) Apelin stimulates myosin light chain phosphorylation in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 26: 1267-1272.
43. Watanabe M, Oike M, Ohta Y, Nawata H, Ito Y, (2006) Sustained contraction and loss of NO production in TGFbeta1-treated endothelial cells. Br J Pharmacol 149: 355-364.
44. Skalli O, Bloom WS, Ropraz P, Azzarone B, Gabbiani G, (1986) Cytoskeletal remodeling of rat aortic smooth muscle cells in vitro: relationships to culture conditions and analogies to in vivo situations. J Submicrosc Cytol 18: 481-493.
45. Owens GK, Loeb A, Gordon D, Thompson MM, (1986) Expression of smooth musclespecific alpha-isoactin in cultured vascular smooth muscle cells: relationship between growth and cytodifferentiation. J Cell Biol 102: 343-352.
46. Dimitropoulou C, White RE, Fuchs L, Zhang H, Catravas JD, et al. (2001) Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca)) channels. Hypertension 37: 301-307.
47. Fukada SY, Tirapelli CR, de Godoy MA, de Oliveira AM, (2005) Mechanisms underlying the endothelium-independent relaxation induced by angiotensin II in rat aorta. J Cardiovasc Pharmacol 45: 136-143.
48. Kilian P, Campbell S, Bilodeau L, Guimond MO, Roberge C, et al. (2008) Angiotensin II type 2 receptor stimulation increases the rate of NG108-15 cell migration via actin depolymerization. Endocrinology 149: 2923-2933.
49. Lee JH, Xia S, Ragolia L, (2008) Upregulation of AT2 receptor and iNOS impairs angiotensin II-induced contraction without endothelium influence in young normotensive diabetic rats. Am J Physiol Regul Integr Comp Physiol 295: R144-R154.
50. Carrillo-Sepúlveda MA, Barreto-Chaves ML, (2010) Phenotypic modulation of cultured vascular smooth muscle cells: a functional analysis focusing on MLC and ERK1/2 phosphorylation. Mol Cell Biochem 341: 279-289.
51. Batenburg WW, Garrelds IM, Bernasconi CC, Juillerat-Jeanneret L, van Kats JP, et al. (2004) Angiotensin II type 2 receptor-mediated vasodilation in human coronary microarteries. Circulation 109: 2296-2301.
52. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, et al. (1999) Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 104: 925-935.
53. Ojamaa K, Kenessey A, Klein I, (2000) Thyroid hormone regulation of phospholamban phosphorylation in the rat heart. Endocrinology 141: 2139-2144.
54. Takahashi T, Taniguchi T, Konishi H, Kikkawa U, Ishikawa Y, et al. (1999) Activation of Akt/protein kinase B after stimulation with angiotensin II in vascular smooth muscle cells. Am J Physiol 276: H1927-H1934.